Hyphens Pharma International Limited announced that the botulinum toxin formulation Nabota from Daewoong Pharmaceutical Co. Ltd. ("Daewoong Pharmaceutical") has been successfully registered in Malaysia on 7 August 2023. Botulinum toxin, commonly referred to as botox, is a neuromodulator for cosmetic use, such as facial wrinkle improvement.

Nabota is a premium high-purity botulinum toxin based on Daewoong Pharmaceutical's patented Hi-PureTM technology that minimises impurities, and is characterised by its high safety, rapid effect, and uniform spreading power. Nabota is approved by the U.S. Food and Drug Administration and the Company's subsidiary Hyphens Pharma Sdn. Bhd.

will be handling the distribution and sales in Malaysia.